ID

29220

Description

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00614120

Lien

https://clinicaltrials.gov/show/NCT00614120

Mots-clés

Versions (1)
  1. 08/03/2018 08/03/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

8 mars 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes NCT00614120

Anglais

Eligibility Diabetes NCT00614120

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00614120
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (oads) for the last 3 months
Description

Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral Quantity

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C1265611
hba1c: 7.0-11.0% (both incl.) for subjects on oad alone
Description

Glucohemoglobin measurement | Antidiabetics Oral Alone

Type de données

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205171
hba1c: 7.0-10.0 % (both incl.) for subjects on oad combination therapy
Description

Glucohemoglobin measurement | Antidiabetics Oral | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3]
C0009429
bmi less than 45.0 kg/m^2
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with insulin within the last 3 months prior to the trial
Description

Insulin regime

Type de données

boolean

Alias
UMLS CUI [1]
C0557978
impaired liver or/and renal function
Description

Liver Dysfunction | Renal Insufficiency

Type de données

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C1565489
significant cardiovascular disease over the last 6 months
Description

Cardiovascular Disease Disease length

Type de données

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0872146
known retinopathy or maculopathy
Description

Retinal Disease | Disorder of macula of retina

Type de données

boolean

Alias
UMLS CUI [1]
C0035309
UMLS CUI [2]
C0730362
recurrent major hypoglycaemia or hypoglycaemic unawareness
Description

Recurrent severe hypoglycemia | Loss of hypoglycemic warning

Type de données

boolean

Alias
UMLS CUI [1]
C0342316
UMLS CUI [2]
C0342317
Retour au début de la page

Similar models

Eligibility Diabetes NCT00614120

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00614120
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral Quantity
Item
subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (oads) for the last 3 months
boolean
C0011860 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Glucohemoglobin measurement | Antidiabetics Oral Alone
Item
hba1c: 7.0-11.0% (both incl.) for subjects on oad alone
boolean
C0202054 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205171 (UMLS CUI [2,3])
Glucohemoglobin measurement | Antidiabetics Oral | Combined Modality Therapy
Item
hba1c: 7.0-10.0 % (both incl.) for subjects on oad combination therapy
boolean
C0202054 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3])
Body mass index
Item
bmi less than 45.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Insulin regime
Item
treatment with insulin within the last 3 months prior to the trial
boolean
C0557978 (UMLS CUI [1])
Liver Dysfunction | Renal Insufficiency
Item
impaired liver or/and renal function
boolean
C0086565 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
Cardiovascular Disease Disease length
Item
significant cardiovascular disease over the last 6 months
boolean
C0007222 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Retinal Disease | Disorder of macula of retina
Item
known retinopathy or maculopathy
boolean
C0035309 (UMLS CUI [1])
C0730362 (UMLS CUI [2])
Recurrent severe hypoglycemia | Loss of hypoglycemic warning
Item
recurrent major hypoglycaemia or hypoglycaemic unawareness
boolean
C0342316 (UMLS CUI [1])
C0342317 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial